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Abstract
Background: The individual character of pharmacokinetics is of great importance in the risk assessment of new
drug leads in pharmacological research. Amongst others, it is severely influenced by the properties and inter-
individual variability of the enzymes and transporters of the drug detoxification system of the liver. Predicting
individual drug biotransformation capacity requires quantitative and detailed models.
Results: In this contribution we present the de novo deterministic modeling of atorvastatin biotransformation
based on comprehensive published knowledge on involved metabolic and transport pathways as well as
physicochemical properties. The model was evaluated on primary human hepatocytes and parameter identifiability
analysis was performed under multiple experimental constraints. Dynamic simulations of atorvastatin
biotransformation considering the inter-individual variability of the two major involved enzymes CYP3A4 and
UGT1A3 based on quantitative protein expression data in a large human liver bank (n = 150) highlighted the
variability in the individual biotransformation profiles and therefore also points to the individuality of
pharmacokinetics.
Conclusions: A dynamic model for the biotransformation of atorvastatin has been developed using quantitative
metabolite measurements in primary human hepatocytes. The model comprises kinetics for transport processes
and metabolic enzymes as well as population liver expression data allowing us to assess the impact of inter-
individual variability of concentrations of key proteins. Application of computational tools for parameter sensitivity
analysis enabled us to considerably improve the validity of the model and to create a consistent framework for
precise computer-aided simulations in toxicology.
Background
The discovery and development of new drug entities is
strongly handicapped by the circumstance that about
50% of the drug candidates fail in the clinical studies
[1]. About one quarter of candidate drugs fail due to
toxicity or pharmacokinetic (PK) problems [2], and cur-
rently, it is a well known fact, that toxicity is the major
cause of attrition in the drug development process [3].
Therefore, it is quite clear that dangerous properties of
drug entities have to be revealed very early in the drug
evaluation studies [4]. Despite the ever growing effort to
apply computational power towards improving the
understanding and in-silico prediction of drug pharma-
cokinetics and response, the overall impact on preclini-
cal safety testing has been modest.
Application of systems biology holds tremendous pro-
mise because it aims to understand and quantitatively
describe biological phenomena within the framework of
the hierarchical levels of metabolic pathways and regula-
tory networks at the different scales of cells, tissue,
organs and ultimately whole organisms [5,6]. However,
despite emerging consensus that such a holistic
approach is essential to provide the framework of pre-
dictive toxicology, the number of successful case studies
is still minuscule [7-9].
Current activities can be grouped into
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(1) quantitative structure-activity-relationship (QSAR)
methods, computational models based on compound
structure and focused on potential interactions of small
molecules with major classes of proteins such as drug
metabolizing enzymes [10-15], transporters [16] and
receptors [16-18]. Also important are physicochemical
properties of the drug, for example solubility and per-
meability that are estimated from the molecular struc-
ture [19-22].
(2) in vitro kinetics for prediction of in vivo drug
clearance using kinetic data from recombinant cyto-
chromes P450 (CYPs), microsomes and hepatocytes
(IVIVE: in vitro-in vivo extrapolations) [23].
(3) physiologically based PK (PBPK) modeling [24-28]
which considers the anatomical, physiological and che-
mical aspects of ADME (absorption, distribution, meta-
bolism and elimination of the drug) [29-31] in multi-
compartment models [32].
In addition to these simulations based on mathemati-
cal models various computational and bioinformatics
approaches are applied to extract information from high
throughput data of drug response experiments at cellu-
lar, tissue, organ and whole organism level.
A critical assessment of the aforementioned tools,
essentially to outline gaps that must be addressed for
more reliable predictive simulation-based toxicology,
indicates needs for more rigorous network models
focusing at systems dynamics beyond kinetics of indivi-
dual enzymes, consideration of inter-individual variabil-
ity and systematic investigations of parameter sensitivity
and its impact on model verification, discrimination and
reduction, to name a few. The first issue is related to
the design of the dynamic models for the drug elimina-
tion process in the hepatocyte, which should be based
on the integration of membrane transport processes for
substrates and products as well as phase I and phase II
reactions. These models need to be tightly linked to sti-
mulus (dose)-response experiments.
The issue of model parameterization in the context of
modeling in toxicology has been already addressed in
1995 by Andersen et al [24]. In addition to the problem
of identifiability, particular attention should be given to
correlation between parameters, very common in biolo-
gical systems.
Yet another question of interest concerns the subtle
integration of the enormous inter-subject variability in
enzymatic phenotypes into the model. This is of outer-
most importance for predictions in toxicology and also
in clinical pharmacology in order to design optimal
treatments for individual patients. Consideration of this
variability in phenotype should rest on quantitative pro-
teomics and activity data from human liver tissue or
hepatocytes representing a statistically significant por-
tion of the population.
The importance of this issue has been extensively
addressed in the review of Rostami-Hodjegan and
Tucker [23] and discussed in the context of IVIVE (in
vitro-in vivo extrapolation) approach. Significant pro-
gress has been made by this group through a strategy
which is based on the simulation of drug disposition in
virtual liver populations. The basic idea of this method
is to portray the variability into the rmax/KM-values
estimated from in vitro studies using human liver
microsomes, primary or cryopreserved hepatocytes or
recombinant expressed enzymes. This is a promising
approach; however, improvement of the strategy is ima-
ginable by separation of the two parameters rmax and
KM (maximal enzymatic rate and enzymatic affinity
parameter in Michaelis-Menten- and derived kinetics).
This concept, which is a focus of the present article, is
driven by the possibility to incorporate separate infor-
mation from pharmacokinetics and quantitative proteo-
mics as well as future incorporation of the regulatory
network responsible for variation of expression level of
the enzymes, transporters and receptors. As model drug
we chose atorvastatin (AS), one of the most frequently
used 3-hydroxymethylglutaryl coenzyme A reductase
inhibitors (statins). Statins thereby reduce cholesterol
synthesis and they also stimulate the uptake of LDL-
cholesterol from the blood. Although they are relatively
safe drugs, the lipid-lowering effect of statins is inade-
quate in some patients, and unpredictable drug-drug
interactions can occur, as well as hepatic and extrahepa-
tic adverse effects including hepatotoxicity, myopathy,
and rare but severe rhabdomyolysis.
Some aspects of dynamic modeling of statins have
been tackled in previous studies, including the determi-
nistic modeling of transport kinetics [33,34] and the
pharmacokinetic modeling of the clearance mechanisms
including consideration of unspecific binding effects
[35]. In the latter case, a multi-compartmental model
approach has been derived on isolated rat hepatocytes.
However, the metabolism of AS inside the liver cell has
not been described in details, missing the kinetic
description of the different metabolite formations, which
thus far precludes the consideration of inter-individual
variability, apart from the fact that rat hepatocytes had
been investigated.
This study describes a deterministic modeling
approach of the dynamic biotransformation and trans-
port processes of AS in human hepatocytes considering
both kinetics of transport processes as well as intracellu-
lar detoxification processes via Phase I and Phase II
enzymes. Attention is given to the detailed enzymatic
and chemical reactions, including conversions between
the acid and lactone form of AS as well as unspecific
binding between metabolites and macromolecules like
proteins. The additional integration of quantitative
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protein data of Phase I and Phase II enzymes enables
the dynamic analysis of the underlying inter-individual-
variability of expression levels of these enzymes.
Methods
Chemicals
Williams Medium E (WME) without phenol-red and
without L-glutamine and stabilized L-glutamine were
obtained from Pan-Biotech-GmbH (Aidenbach, Ger-
many). Penicillin/Streptomycin and ITS-X were obtained
from Invitrogen (Karlsruhe, Germany). Bovine serum
albumin (BSA) and dimethyl sulfoxide (DMSO) were
purchased from Sigma-Aldrich Chemicals (Taufkirchen,
Germany). Dexa Inject was obtained from Jenapharm
(Jena, Germany). AS, its metabolites and deuterated
standards were purchased from Toronto Research Che-
micals Inc. (North York, Canada). PBS was obtained
from Invitrogen (Karlsruhe, Germany) and Complete
Mini, EDTA-free from Roche Diagnostics (Mannheim,
Germany). NaPP, sucrose and LiChrosolv were pur-
chased from Merck (Darmstadt, Germany); acetonitrile
from Roth (Karlsruhe, Germany), formic acid from
Fluka, (Germany), UGT1A3 monoclonal mouse antibody
from Abcam (Cambridge, England). Trypsin was pur-
chased from Promega (Mannheim, Germany). Synthetic
peptides were purchased from Sigma-Genosys (Haver-
hill, UK).
Isolation and cultivation of primary human hepatocytes
Tissue samples from human liver resections were
obtained from patients undergoing partial hepatectomy.
Experimental procedures were performed according to
the guidelines of the charitable state-controlled founda-
tion HTCR (Human Tissue and Cell Research) Regens-
burg, Germany, and the institutional guidelines for liver
resections of tumor patients with primary or secondary
liver tumors, Technical University Munich, MRI,
Munich, Germany. The use of human hepatocytes for
research purposes was approved by the local ethics com-
mittees of the Ludwig-Maximilians-University of
Munich [36] and the Charité, Humboldt University Ber-
lin [37], Germany, and written informed consent was
obtained from all patients. Hepatocytes were cultured
on collagen gel precoated 6-well plates at a density of
1.5·106 cells/well. Cells were allowed to attach to the
collagen layer. After transport, culture media was dis-
posed and attached cells were cultured 24 h at 37°C in a
humidified chamber with 95%/5% air/CO2 in serum-free
medium WME, supplemented with albumin (0.1% (v/v)),
penicillin/streptomycin (100 U/ml), stabilized L-gluta-
mine (2 mM), dexamethasone dihydrogenphosphate
(0.025% (v/v)) and ITS-X (5 mg insulin, 3.35 μg
natrium-selenit, 2.75 mg transferrin and 1 mg ethanola-
mine), further named SFM.
Time-series experiments
Incubation with AS was started by disposing the culture
media and cultivation of the attached cells at 37°C in a
humidified chamber with 95%/5% air/CO2 in 2 ml SFM,
supplemented with 10 μM AS, 0.1% (v/v) BSA and 0.1%
DMSO. At specified time-points, three wells were
further treated for the preparation of samples for the
measurement of extracellular and intracellular metabo-
lites, respectively. SFM media was collected and 50 μL
formic acid and deuterated internal standard was added
for the further measurement of extracellular metabolites.
Cells were harvested in pre-cooled albumin-free SFM,
disrupted by freeze/thaw and ultra-sonification and cen-
trifuged. The supernatant was used for the determina-
tion of intracellular metabolites.
For the preparation of samples for the protein mea-
surements, culture medium was disposed and cells were
harvested in pre-cooled PBS, supplemented with Com-
plete Mini EDTA-free (1 Tablet/10 ml Buffer). Cell sus-
pensions were centrifuged 5 min (500 g) at 4°C and cell
pellets were resuspended in 150 μL NaPP-buffer (0.1 M,
pH 7.4), containing 250 mM sucrose and Complete
Mini EDTA-free (1 Tablet/10 ml Buffer). Cells were dis-
rupted by ultra-sonification and lyophilized for the ana-
lysis of total protein concentration, CYP3A4 and
UGT1A3 content.
For cell number determination, cells from two wells
were fixed with methanol-acetic acid fixative solution
(10 min at 37°C and 4°C) and afterwards nuclei were
stained for 15 min with Meyers Hämalaun (Sigma-
Aldrich Chemie GmbH, Germany), rinsed with water
and air-dried. Stained nuclei were counted in digital
images (10 per well) at 40-fold Magnification (ImageJ
Image Processing and Analysis Program).
Quantification of atorvastatin and its metabolites
AS and ASL, and their para- (ASpOH, ASLpOH) and
ortho-hydroxy-metabolites (ASoOH, ASLoOH), were
determined by LC-MS-MS analysis using the respective
deuterium labeled analogues as internal standards,
essentially as described [38]. HPLC separation was per-
formed at 30°C on a XBridge Shield RP18 column (2.1
× 50 mm, 3.5 μm, Waters) using (A) 1 mM formic acid
and (B) acetonitrile as mobile phases at a flow rate of
0.4 ml/min. Gradients were programmed as follows:
63% A for 4 min; linear decrease of A to 60% within 9
min; linear decrease of A to 55% within 2.5 min; 55% A
for 1 min; increase of A to 63% in 0.2 min. Equilibration
time of the column was 20 min. MS-MS analysis was
performed on an Esquire HCT ultra ion trap mass spec-
trometer (Bruker Daltonics, Bremen, Germany) coupled
to an HPLC 1100-System (Agilent, Waldbronn, Ger-
many) consisting of binary pump G1312A, degasser
G1379A, well-plate sampler G1367A and column
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thermostat G1330B. The ionization mode was electro-
spray (ESI), polarity positive, mass range mode ultra-
scan, and nitrogen was used as a drying and nebulizer
gas. The following parameters were applied: nebulizer
45 psi, dry gas 10 l/min, dry temperature 300°C, capil-
lary 4100 V, scan range 200 - 600 m/z.
Precursor and product ions (m/z) of analytes and inter-
nal standards, respectively, were ATV (559 and 440.2;
466.2), [2H5]ATV (564 and 445.2; 471.2), ATV-L (541.2
and 448.2), [2H5]ATV-L (546.2 and 453.2), p-OH-ATV
(575 and 440.2; 466.2), [2H5]p-OH-ATV (580 and 445.2;
471.2), p-OH-ATV-L (557 and 448.4), [2H5]p-OH-ATV-L
(562 and 448.4), o-OH-ATV (575 and 466.4), [2H5]o-OH-
ATV (580 and 471.2), o-OH-ATV-L (557 and 448.4),
[2H5]o-OH-ATV-L (562 and 448.4). Sample quantifica-
tion was possible in a range from 0.5 to 500 pmol.
CYP3A4 and UGT1A3 protein quantification
Protein quantification of CYP3A4 and UGT1A3 in
human liver microsomes and relative protein quantifica-
tion of UGT1A3 in lyophilized samples of primary hepa-
tocytes was performed by immunoblotting as described
previously [38,39].
Cell lysates for absolute quantification analysis of
CYP3A4 were prepared from lyophilized human primary
hepatocytes by sonification in the presence of glass
beads in buffer containing Complete Mini-Protease Inhi-
bitor Cocktail, and following homogenization. In the
CYP3A4 quantification assay, three synthetic isotopically
labeled peptides (13C/15N amino acid) were used as
internal standard for calibration. These isotope labeled
standard peptides represented sequence analogues to
proteotypic peptides of CYP3A4, which arise from tryp-
tic digestion. After acetone precipitation and resolving
of the proteins in 8 M Urea, a definite amount of inter-
nal standard peptides was added. The sample mixture
was reduced with 5 mM DTT and alkylated with 15
mM iodacetamide in 50 mM ammonium bicarbonate.
Subsequently samples were digested with trypsin at 42°C
for 4 h (enzyme/substrate ratio of 1:10). Efficiency of
tryptic digestion was checked by SDS-PAGE followed by
silver staining. The resulting peptides were purified
using C18 OMIX® Tips (Varian, Darmstadt, Germany)
according to manufacturer’s suggested protocol and
separated on a nanoliter-flow Ultimate HPLC system
(Dionex, Idstein, Germany). After injection (15 μl), pep-
tides were trapped and desalted on a precolumn (0.3
mm I.D. × 5 mm PepMapTM, Dionex) at a flow rate of
30 μl/min in 0.1% TFA for 6 min. Peptides were trans-
ferred to the separation column (75 μm I.D. × 250 mm
PepMapTM column, Dionex) and separated in a linear
gradient of mobile phase (A: 0.1% formic acid, B: 84%
acetonitrile/0.1% formic acid) from 5% B to 35% B over
a period of 35 min with a flow of 290 nl/min. The
column effluent was continuously directed into the
NanoSpray II source of a 4000QTrap mass spectrometer
(Applied Biosystems, Foster City, CA, USA). The MS
was set up to run a multiple reaction monitoring experi-
ment essentially, as described previously [40], including
two to three parent-to-product ion transitions for each
internal standard peptide as well as the corresponding
transitions of native peptide of CYP3A4. The instrument
settings were as follows: ion spray voltage, 3-4 kV; inter-
face heater, 150°C; declustering potential, 50 V; collision
energy, peptide specific; entrance potential, 10 V; colli-
sion cell exit potential, 10 V. MS data were processed
by integrating the appropriate peak areas from extracted
ion chromatograms by MultiQuantTM Software
(Applied Biosystems). The absolute amount of CYP3A4
protein was calculated from the peak area ratio “internal
standard peptide/native peptide”. Total protein content
of the samples were determined by amino acid analysis
(AAA) on a Waters 2695 HPLC system using the
AccQ•Tag derivatization method (Waters, Eschborn,
Germany), according to manufacturer’s instructions.
Identification of metabolic network structure
Numerous metabolic and physicochemical aspects about
AS had to be considered in the initial model building.
AS exists in two forms, a very lipophilic lactone (ASL)
and a comparably hydrophilic hydroxyl-acid (AS). AS is
converted enzymatically via an instable intermediate
product into ASL, mediated by different UGT isoen-
zymes [41,42]. Recent investigations by ourselves and
others have shown that the most important contributor
to UGT-driven lactonization is UGT1A3, whereas
UGT1A1 plays an insignificant role [38,42]. AS acids
and lactones are inter-converted chemically into each
other [43]. However, studies have indicated, that the
chemical lactonization of AS to ASL can be neglected at
physiological pH of 7.4 [43]. Recent studies highlight,
that different PON enzymes might also be possible con-
tributors to the lactone hydrolysis and that PON1 is
present in liver [44-48].
Both AS and ASL are hydroxylated in human hepato-
cytes leading to para- and ortho-hydroxy-metabolites,
ASpOH, ASoOH, ASLpOH and ASLoOH [49,50],
mainly catalyzed by CYP3A4 [51]. Recent studies have
reported, that CYP2C8 and CYP3A5 also hydroxylate
AS to a minor extent [50,52].
Furthermore, AS is transported into the cell via
organic anion transport polypeptides (OATP), and
recent studies on recombinant systems showed, that
OATP1B1 and OATP2B1 contribute to the AS import
[53,54], which are both expressed in the human liver
[55,56]
OATP1B3 is supposed to be also a main contributor
to drug transport [54], since it shows high gene
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expression levels in liver [57], but its importance for AS
has not been investigated kinetically so far.
OATP transporters have been reported to be bidirec-
tional facilitated diffusion transporters, independent
from ATP and Na+, K+ and H+, but with a possible
involvement of reduced glutathione [58,59]. However,
previous investigations on transport mechanisms on rat
hepatocytes, showed, that the intracellular concentra-
tions of pitavastatin and other compounds are much
higher than outside the cell [33,34,60]. Facilitated or
passive diffusion do not allow a greater intracellular
than extracellular concentration of the parent drug of
interest, when the source is the initial extracellular
concentration, because it is a concentration-gradient
dependent mechanism. Therefore, the import mechan-
ism should be rather considered as active mediated
transport, which is not concentration-gradient depen-
dent, rather than as the proposed facilitated diffusion
process.
As shown with the recombinantly expressed transpor-
ters mentioned above [54], transport of the acidic meta-
bolites, ASpOH and ASoOH, by OATP1B1 was similar
to that of AS, and transport of the corresponding lac-
tones was also mediated by this transporter, although at
somewhat lower rates. We therefore assumed that the
same OATP transporters are responsible for the import
of AS and its hydroxylated and lactone metabolites into
hepatocytes.
AS and its hydroxylated metabolites, ASpOH and
ASoOH, are actively exported out of the hepatocytes
into the bile by the ATP-dependent MDR1 transporter
[61,62]. In addition, acidic and lactone form of AS
showed inhibitory effects in transport studies of sub-
strates of MDR1 and MRP2 [63-65], pointing to the
competitive transport mechanism of these substrates at
this proteins. Further, the transporters MRP1, MRP3
and MRP6 are also reported to be responsible for the
transport of organic compounds including AS from
inside the hepatocytes into the plasma [56,66].
Passive diffusion might play also an important role in
the transfer of AS, ASL and the corresponding metabo-
lites, ASpOH and ASoOH, ASLpOH and ASLoOH,
respectively. Since the acidic forms of AS are rather
hydrophilic and the lactone forms of AS are rather lipo-
philic, it can be assumed that passive diffusion plays a
more important role for the lactone forms, and the
transporter mediated active transport plays a more
important role for the acidic forms, as reported earlier
for statins [67].
Finally, lipophilic drugs have a high affinity to bind
non-specifically to proteins, and previous studies con-
centrated on the modeling of drug binding in the intra-
cellular and the extracellular space as well as on the
surface of the cells [60,68,69].
Mathematical modeling
The mathematical model can be described by the system
of non-linear ordinary differential equations
d
(
cjVcomp
)
dt
=
∑
i
νijrij = f (c,p, t) (1)
where the change in extracellular, intracellular or
unspecific bound metabolite concentration cj in the
extra - or intracellular compartment with Vcomp is
effected by the conversion or production of contributing
chemical or enzymatic reactions or by transport steps
rij, respectively. The extracellular volume, V
m
comp, equals
to the volume of the media used. The intracellular
volume, Vccomp, equals to the total volume of all cells
used, and is determined by multiplying the cell number
by the volume of a single hepatocyte, estimated to be
14.1 pL by the approximation of a spherical shape with
a diameter of 30 μm [70].
Appropriate reaction kinetics rij are modeled for the
CYP3A4 hydroxylation, the UGT1A3 lactonization, the
chemical and enzymatic lactone hydrolysis and intracel-
lular unspecific binding to macromolecules.
Previous studies determined substrate inhibition
kinetics of the CYP3A4 mediated hydroxylation of AS
on human microsomes [52]. However, inhibition effects
contribute severely only at a concentration higher than
100 μM. Furthermore, our model approach considers
the competitive nature of alternative substrates, by inte-
grating the CYP3A4 hydroxylation of AS and ASL as
reaction kinetics describing the competitive conversion
of alternative substrates to alternative products,
illustrated for the hydroxylation of AS to ASpOH
r3A4,ASpOH =
rmax,3A4,ASpOH
cAS
KM,3A4ASpOH
1 +Den
Den =
cAS
KM,3A4,ASpOH
+
cAS
KM,3A4,ASoOH
+
cASL
KM,3A4,ASLpOH
+
cASL
KM,3A4,ASLoOH
(2)
(see Additional file 1 - Derivation of Atorvastatin
kinetics at CYP3A4).
The lactonization of AS to ASL is mediated by
UGT1A3 enzymes and the reaction is formulated as
substrate inhibition kinetics [41].
r1A3,AS =
rmax,1A3,AS · cAS
KM,1A3,AS + cAS +
(cAS)2
KI,1A3,AS
(3)
The lactone metabolites are either hydrolyzed chemi-
cally to the respective acid metabolites [43] inside (c) or
outside (m) the cell, or enzymatically by the contribution
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of PON enzymes inside the cell. Both reactions are
described as first order kinetics
rhyd,j = kCR · cc/mj j + kPON,j · ccj . (4)
Unspecific binding of intracellular metabolites to
macromolecules is formulated as
rbind,j = kdis
((
1
f uj
− 1
)
ccj − cbj
)
, (5)
with the dissociation coefficient kdis and the intracellu-
lar fraction unbound [71]
f uj =
ccj,eq
ccj,eq + c
b
j,eq
, (6)
which describes the ratio between the intracellular free
concentration ccj to the sum of intracellular free and
bound concentration, ccj and c
b
j , in equilibrium (index eq)
(see Additional file 2 - Derivation of kinetics of unspeci-
fic protein binding). However, the intracellular free and
bound concentrations in equilibrium are not measur-
able; therefore, the fraction unbound fuj is set as a para-
meter to be estimated in the parameter optimization
procedure.
Transport steps include active import and export of
the metabolites as well as passive diffusion steps. Both
active import by OATP1B1 or OATP2B1 and export
of AS are described as Michaelis-Menten-kinetics
[53,54]
rim/ex,AS =
rmax,1B1/2B1/ex,AS · cAS
KM,1B1/2B1/ex,AS + cAS
, (7)
whereas the active transport kinetics of the other
metabolites are assumed to be of first-order [72].
rim/ex,j = kim/ex,j · cc/mj . (8)
Besides the active transport, metabolites undergo pas-
sive diffusion through the double-layer lipid-membrane.
Passive diffusion, described as
rdiffj =
Dj
d
· Acells ·
(
cmj − ccj
)
,
= Pj ·
(
cmj − ccj
) (9)
is driven by the concentration difference between
outside and inside the cell,
(
cmj − ccj
)
, over the lipid-
membrane with thickness d, through all cells with the
total surface area Acells, and controlled by the diffusion
coefficient Dj and is comprised as the permeability
coefficient Pj.
Optimization procedure for estimation of model
parameters
The optimization procedure is based on evolutionary
strategies which are implemented with JavaEva (WSI
Computer Science Department, Center for Bioinfor-
matics, University of Tübingen, Germany) and a MVA
(main vector adaptation) mutation operator [73]. The
optimization procedure estimates the parameters in
equations (2) to (9) based on the optimization criterion
 = arg min
p
N∑
n=1
J∑
j=1
(
ccalcj,n − cmeasj,n
sj
)2
, (10)
where the deviation of calculated and measured con-
centrations divided by the measurement standard devia-
tion sj, squared and summed over all metabolites J and
all time points N, has to reach a minimum. Additional
optimization constraints are fuAS >fuASL, PASL >PAS, PAS
>PASOH and PASL >PASLOH, because the lactones have a
higher lipophilicity than the acids and the metabolites
are supposed to be more hydrophilic than the corre-
sponding parent lactone or acid drug.
The integration of the differential equations (1) using
the reaction kinetics in equations (2) to (9) was performed
by the differential algebraic equation solver LIMEX (Kon-
rad-Zuse-Zentrum für Informationstechnik, Berlin) [74].
Relative abundance approach for prediction of rmax-
parameters
For pharmacokinetic predictions taking inter-individual
variability of CYP3A4 and UGT1A3 expression levels
into account, maximal rate parameters are predicted via
a relative abundance approach, which is based on the
assumption that the maximal rate of the reaction is pro-
portional to the enzyme concentration:
remax ,li,j = r
e
max, reference,j ·
celi
cereference
. (11)
The maximal velocities remax ,i,j of the respective
enzyme e, here CYP3A4 or UGT1A3, in the conversion
to the product Pj in the liver of interest li is estimated
from the respective maximal rate remax ,reference,j and the
enzyme concentration cereference in the reference liver and
the enzyme concentration cei in the liver of interest li.
Computational approach
The mathematical model of AS metabolism was coded
in FORTRAN language and linked to the numerical
integrator LIMEX, also written in FORTRAN. After
compilation to the executable program, optimization
was started by the call of JavaEva. The mathematical
model is supplemented as SBML-file for review purpose.
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Results
Model-setup
The model structure of AS biotransformation in primary
human hepatocytes is schematized in Figure 1 and com-
prises the description of the extracellular, intracellular
and unspecifically bound metabolites, as well as corre-
sponding reaction and transport steps and unspecific
protein binding.
Since the calibration and quality samples were prepared
in the same media as the experimental metabolite samples
and because it can be assumed that the intracellular pro-
tein concentration is much higher compared to the out-
side of the cells, the unspecific protein binding was only
considered for the intracellular space.Regarding the unspe-
cific protein binding, it can be assumed that the intracellu-
lar protein concentration is much higher compared to the
outside of the cells. This assumption is based on the esti-
mation of the ratio of intracellular protein to extracellular
media protein concentration. From the total cell protein
measurement and the determination of total cell volume a
total intracellular protein concentration of about 30 g/l
can be estimated. The media includes as sole protein com-
ponent 0.1% (v/v) albumin, corresponding 1 g/l. Therefore,
this assumption is justified.
Because our hepatocyte culture model does not allow
to distinguish experimentally import and export, single
Medium
Cell
ASpOHASLpOH
ASLoOH ASoOH
CYP3A4
Unspecific
intracellular binding
to macromolecules
UGT1A3
ASG
ASASL
ASASL
OATP1B1
OATP2B1
OATP1B1
OATP2B1
MDR1
MRP2
ASpOHASLpOH
ASLoOH ASoOH
MDR1
MRP2
Figure 1 Scheme of the full model of Atorvastatin metabolism in primary human hepatocytes. The scheme illustrates atorvastatin
metabolic and transport pathways in human hepatocytes. The model comprises the active import and export of AS and ASL, and corresponding
para- and ortho-hydroxy-metabolites, ASpOH and ASoOH, ASLpOH and ASLoOH, mediated by import proteins, OATP1B1 and OATP2B1 (solid
lines), and export proteins, MDR1 and MRP2 (solid lines), as well as passive diffusion steps (dashed lines). AS and ASL are hydroxylated to the
corresponding metabolites by CYP3A4, respectively (solid lines). Compound AS is converted via an instable glucuronid-intermediate to ASL
mediated by UGT1A3 (solid lines). The lactones are hydrolyzed either chemically or enzymatically by putative PON to the respective acids (solid
and dotted line). Acids and lactones are further subject to unspecific binding to macromolecules in human hepatocytes (dashed lines).
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irreversible, actively mediated transport steps for both
directions, as well as passive diffusion steps were consid-
ered for each compound, respectively, similar to
mechanistic transport models of other studies [33,34].
Only in the case of AS different transport steps for
OATP1B1 and OATP2B1 were implemented in the
model, because specific KMs had been determined in
previous studies [53,54].
Model verification
Model verification was performed by quantitative mea-
surements of AS and all metabolites in the extra- and
intracellular space during time-series experiments, per-
formed first on a single batch of primary hepatocytes
from a single individual 1. Special emphasis was given
to the issue of parameter sensitivity and correlation
between parameters to improve the quality of the
model.
Time series/stimulus-response measurements on primary
human hepatocytes
From the metabolite concentrations in primary human
hepatocytes of individual 1 (see Additional file 3 - Ator-
vastatin metabolite concentrations from the time-series
experiment on primary human hepatocytes of individual
1) we calculated total recovery at each time point (Table
1). The recovery is calculated from material balance
equations and is defined as the sum of intracellular and
extracellular metabolite amounts at the respective time-
point divided by initial AS amount. As evident from
Table 1, the total recovery was close to 100% after ten
minutes but decreased at higher time-points. This may
be explained by unspecific protein binding leading to
the pool of bound metabolites, which increases over
time due to intracellular accumulation of metabolites.
This result points to the necessity and importance of
the implementation of unspecifically bound metabolites
in the model.
Parameter estimation
Parameter optimizations were performed with aid of
evolutionary algorithms (JavaEva, μ = 8 parent and l =
4 children) and using the nominal parameter values of
the reactions, transport and diffusion steps in equations
(2) to (9). The optimization criterion in equation (10)
was used, which demands to minimize the difference
between experimental concentration data and model
simulation. In the optimization procedure certain para-
meters were fixed to values (Table 2), which were either
identified in or assumed from previous investigations.
The Michaelis-Menten constants KM of the CYP3A4
hydroxylation and of the AS transporters OATP1B1 and
OATP2B1 were fixed to values determined with recom-
binant enzymes [50,53,54]. The KM and KI of the
UGT1A3-lactonization were fixed to values determined
on human liver microsomes [41]. The rate constant of
spontaneous hydrolysis of ASL, kCR, was estimated from
experimental observations [43] and assumed to be same
for the hydrolysis of the lactone metabolites, ASLpOH
and ASLoOH, respectively. The dissociation rate con-
stant kdis of unspecific binding was fixed to a value, con-
sidered to be very high in a previous study on modeling
of protein binding mechanisms [33].
Analysis of the predicted concentration-time-profiles
The model predicted concentration-time-profiles are
illustrated together with the measured concentrations
(see Additional file 3 - Atorvastatin metabolite concen-
trations from the time-series experiment on primary
human hepatocytes of individual 1) in Figure 2. Both
intracellular AS and ASL are converted to the corre-
sponding para- and ortho-hydroxy metabolites, ASpOH
and ASoOH, and ASLpOH and ASLoOH, respectively.
However, the acidic metabolites, ASpOH and ASoOH,
Table 1 Recovery of atorvastatin metabolites in the time-
series experiment on primary human hepatocytes of
Individual 1
time [min] Recovery [%]
0 100
10 97.6
30 96.8
60 94.8
120 88.8
180 86.5
240 89.0
300 89.0
360 80.8
480 n.o.
600 78.2
The recovery, calculated from material balance equations at each
experimental time-point, is defined as the sum of intracellular and
extracellular metabolite amounts divided by measured initial atorvastatin acid
amount (n.o.: not observed) (see Additional file 3 - Atorvastatin metabolite
concentrations from the time-series experiment on primary human
hepatocytes of individual 1).
Table 2 Parameters which were fixed in the optimization
procedure to literature values
Parameter Value Units Literature
KM,3A4,ASpOH 25600 pmol·ml
-1 [50]
KM,3A4,ASoOH 29700 pmol·ml
-1 [50]
KM,3A4,ASLpOH 1400 pmol·ml
-1 [50]
KM,3A4,ASLoOH 3900 pmol·ml
-1 [50]
KM,1B1,AS 18900 pmol·ml
-1 [54]
KM,2B1,AS 200 pmol·ml
-1 [53]
KM,1A3,AS 12000 pmol·ml
-1 [41]
KI,1A3,AS 75000 pmol·ml
-1 [41]
kCR 0.0025 min
-1 [43]
kdis 600 min
-1 [33]
Parameter values were adopted from literature sources outlined in the right
column.
Bucher et al. BMC Systems Biology 2011, 5:66
http://www.biomedcentral.com/1752-0509/5/66
Page 8 of 19
show higher intracellular concentrations than the
lactone metabolites, ASLpOH and ASLoOH. The ratio
between intracellular AUC0-600 min of the acidic form to
that of the lactone form equals 20.1 in case of the para-
hydroxy-metabolites and 23.6 in the case of the ortho-
hydroxy-metabolites.
Accordingly, the extracellular concentrations of the
acidic metabolites are higher than that of the lactone
metabolites. The ratio between extracellular AUC0-600
min of the acidic form to that of the lactone form equals
54.3 in case of the para-hydroxy-metabolites and 70.8 in
the case of the ortho-hydroxy-metabolites.
Further, the results show that the components have
higher concentrations in the intracellular space than
outside the cell. The ratio of intracellular AUC0-600 min
to extracellular AUC0-600 min equals minimally 4.5 in the
case of ASoOH and maximally 38.2 in the case of ASL-
pOH. Similarly, the ratio of intracellular cmax to extra-
cellular cmax equals minimally 2.5 in the case of ASoOH
and maximally 34.5 in the case of ASLpOH.
Simultaneous model verification on different individual
hepatocyte donors
The process of model verification so far has been
applied on a single experiment on primary human hepa-
tocytes of individual 1. In the next step it has to be pro-
ven, that the model is also capable to describe different
individual metabolic profiles, especially being further
able to reflect the inter-individual parameter variability,
not only in the parameters rmax of the phase I and II
reactions, but also in the transporters. Therefore, the
model verification is performed based on AS biotrans-
formation data on primary hepatocytes from three dif-
ferent individuals simultaneously.
Therefore, maximal rate constants rmax of CYP3A4
hydroxylation and UGT1A3 lactonization were predicted
for individual 2 and 3 via the relative abundance
approach (equation (11)) using the rmax-parameters of
individual 1 (Table 3) and the protein concentrations
observed on the primary human hepatocytes (Table 4).
These parameters were then fixed in the optimization.
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Figure 2 Measured concentrations and simulated fits of Atorvastatin compounds, individual 1 . Displayed are the measured
concentrations (rhombs) with mean and standard deviation (n = 3) of Atorvastatin compounds in the culture medium (upper two rows) and
free Atorvastatin compounds inside primary hepatocytes (lower two rows) of individual 1, and corresponding simulation profiles (solid lines). First
and third row: AS (left), ASpOH (middle) and ASoOH (right). Second and fourth row: ASL (left), ASLpOH (middle) and ASLoOH (right).
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Further, the rate constants k of PON mediated lactone
hydrolysis of individual 2 and 3 were estimated in the
optimization procedure.
However, the analysis of parameter sensitivity and
identifiability (see Additional file 4 - Analysis of para-
meter sensitivity and following model reduction proce-
dure) showed that the first order kinetics of OATP1B1
mediated import is favored over the zero-order kinetics
of OATP2B1 import of AS, and that the first order
kinetics are hard to distinguish from first order passive
diffusion mechanisms in this evaluation system. Thus, in
the following, mechanisms of active transport and pas-
sive diffusion are lumped, resulting in the apparent
transport rate for import,
rim,j = kim,j · cmj + Pj · cmj = κim,j · cmj , (12)
and in the apparent transport rate for export
rex,j = kex,j · ccj + Pj · ccj = κex,j · ccj , (13)
described by the product of apparent rate constant
im/ex of import or export and extra- or intracellular
concentration cm/cj , respectively (Figure 3). Consequently,
the rate constants  of import and export are set indivi-
dually, and were to be estimated in the optimization
procedure.
The simultaneous model verification was performed
based on the stimulus response data obtained from pri-
mary human hepatocytes of individual 1 (see Additional
file 3 - Atorvastatin metabolite concentrations from the
time-series experiment on primary human hepatocytes
of individual 1), individual 2 (see Additional file 5 -
Atorvastatin metabolite concentrations from the time-
series experiment on primary human hepatocytes of
individual 2) and individual 3 (see Additional file 6 -
Atorvastatin metabolite concentrations from the time-
series experiment on primary human hepatocytes of
individual 3), respectively.
The model prediction is in satisfying agreement with
experimental data of individual 2 (Figure 4). However,
in case of individual 3, the model prediction is compar-
ably poor, because there are relatively high deviations,
especially with the intracellular metabolites ASL and
ASoOH and extracellular ASpOH (Figure 5, solid line).
One reason could be the extended contribution of beta-
oxidation in AS metabolism. Beta oxidation at the
heptanoic acid side chain is a typical transformation
pathway for all statins, but is reported to play only a
minor role in humans [75]. However, high activity of
beta-oxidation of fatty acids, which is responsible for the
supply of ATP for gluconeogenesis in type 2 diabetes
mellitus [76,77], which individual 3 was diagnosed with,
may severely influence the AS metabolism. To test this
hypothesis, respective reactions with the acid metabo-
lites as substrates were considered in the model veri-
fication of individual 3, but the results showed no
significant improvement (data not shown). The second
reason could be, that CYP3A4 and UGT1A3 protein
concentrations of individual 3 used in the estimation
of corresponding rmax value via relative abundance
approach (equation (11)) differ from the measured mean
value (Table 4). Due to the fact that the rmax parameters
of CYP3A4 and UGT1A3 show high sensitivities in the
parameter sensitivity analysis (see Additional file 4 -
Analysis of parameter sensitivity and following model
reduction procedure), a variation in the values would
have a high impact on the metabolic profiles. Therefore,
in a further optimization step, the CYP3A4 protein con-
centrations are allowed to vary in the interval of mean ±
standard deviation (Table 4), where the standard devia-
tion of UGT1A3 protein concentration is assumed to be
30% of the mean value. Notably, an improvement in the
model prediction on individual 3 could be achieved in
the case of the intracellular metabolites AS and ASL
and extracellular AS (Figure 5, dashed lines). But there
are still major deviations in case of intracellular ASL
and ASoOH and extracellular ASpOH, which could not
be explained any further, but shows, that there must be
some other reactions or effects in the system, which
have not been discovered yet.
The estimated model parameters for individual 1, 2
and 3, summarized in Table 5, display the proposed
parameter variability of enzyme mediated reactions
as well as of the transport steps. However, the rate
Table 3 Verified parameters of CYP3A4 and UGT1A3 in
individual 1
Parameter Value rel. Error [%] Units
rmax,3A4,ASpOH 1108 5.5 pmol·min
-1·ml-1
rmax,3A4,ASoOH 3345 2.3 pmol·min
-1·ml-1
rmax,3A4,ASLpOH 1228 12.7 pmol·min
-1·ml-1
rmax,3A4,ASLoOH 2756 11.6 pmol·min
-1·ml-1
rmax,1A3,AS 956 14.8 pmol·min
-1·ml-1
Parameters are listed with nominal values from optimization and relative
parameter errors from FIM based identifiability analysis (see Additional file 4 -
Analysis of parameter sensitivity and following model reduction procedure) in
the corresponding units shown.
Table 4 Protein concentrations of CYP3A4 and UGT1A3
in primary human hepatocytes
Individual CYP3A4 [pmol ml-1] UGT1A3 [-]
1 1027 ± 107 (n = 2) 1.00
2 611 ± 120 (n = 4) 0.29
3 755 ± 19 (n = 2) 0.10
Protein concentrations were calculated from total CYP3A4 and UGT1A3
content per sample divided by total intracellular volume of hepatocytes,
respectively. Protein concentrations of CYP3A4 are listed in mean and
standard deviation in the units pmol per ml intracellular volume. Relative
protein concentrations of UGT1A3 are normalized to individual 1.
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constants of ASLoOH import and export of individual 2
and of ASL import and export of individual 3 are con-
siderably higher than the other transport rate constants,
which points to strong linear dependencies of these
parameters.
The mathematical model of AS metabolism in human
hepatocytes of individual 1 is supplemented as SBML-
file (see Additional file 7 - Model of atorvastatin meta-
bolism in primary human hepatocytes of individual 1,
and BioModels database).
Dynamic analysis of inter-individual CYP3A4 and UGT1A3
expression level variability
Based on the model version of optimized parameters,
gained in the simultaneous model fit, the effect of inter-
individual variability of CYP3A4 and UGT1A3 protein
expression levels was investigated by linking the protein
expression data of 150 liver samples (Figure 6) via the
described relative abundance approach in equation (11),
using individual 1 as reference. UGT1A3 and CYP3A4
protein concentrations of individual 1 were converted
from based on total protein amount to based on micro-
somal protein amount by multiplying with the factor
0.22, determined in human liver homogenates and cor-
responding microsome fractions via Bradford test [78].
Simulations were performed with an initial extracellu-
lar AS concentration of 50 (pmol ml-1), which is in the
range of physiological plasma concentrations [54,79],
over a time period of 1200 min.
The most important question that arises from this
dynamic analysis was, how the metabolic profiles of the
intracellular metabolites AS, ASpOH and ASoOH are
Medium
Cell
ASpOHASLpOH
ASLoOH ASoOH
CYP3A4
Unspecific
intracellular binding
to macromolecules
UGT1A3
ASG
ASASL
ASASL
ASpOHASLpOH
ASLoOH ASoOH
Figure 3 Scheme of the model used in the simultaneous model verification. In contrast to the full model illustrated in Figure 1, this model
contains lumped transport kinetics, which means, one import and one export rate for each metabolite, respectively. This transport simplification
resulted from the local parameter sensitivity analysis (see Additional file 4 - Analysis of parameter sensitivity and following model reduction
procedure).
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influenced by this variability, since they are considered
to be the active drugs, which inhibit HMGCoA-reduc-
tase [80]. Therefore, AUC, cmax and t(cmax) of the con-
centration-time-profiles of either AS alone or the sum
of concentration of AS, ASpOH and ASoOH were cal-
culated for each liver sample over a time period of 1200
min and the distributions over all liver samples were
evaluated, respectively. Finally, appropriate probability
density functions are fitted to the distributions (Figure 7).
The probability density function characteristics are sum-
marized in Table 6. Obviously, there are differences
between the examination of only AS or the sum of con-
centrations of AS, ASpOH and ASoOH. AUC, cmax and
t(cmax) have lower values in case of AS alone compared
to the sum of all acidic metabolites. The population
mean of AUC is 75051 (pmol ml-1 min) in the case of
AS and 203617 (pmol ml-1 min) in the case of the sum
of AS, ASpOH and ASoOH. Also, cmax is lower in the
case of AS alone, 201 (pmol ml-1), compared to the sum
of the acidic metabolites, 366 (pmol ml-1). Further, the
maximal concentration appears at a shorter time point,
48 min, in the case of AS alone, compared to the time
point, 100 min, of the sum of AS, ASpOH and ASoOH.
The results are quite explainable, since ASpOH and
ASoOH are the hydroxylated products of AS and there-
fore their maximal concentrations event at a delayed
time-point compared to AS.
Further, except for the AUC of AS, the probability den-
sity functions show a very narrow shape, regarding the
relative standard deviation, when comparing to the sample
standard deviations of the underlying distribution of
CYP3A4 and UGT1A3, respectively. The probability den-
sity functions fitted to CYP3A4 and UGT1A3 distributions
have a relative standard deviation of 259% and 137%,
respectively, whereas the relative standard deviations of
the probability density functions of AUC, cmax and t(cmax)
are lower than 50%, except for the probability density
function of AUC of intracellular AS, which equals 123%.
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Figure 4 Measured concentrations and simulated fits of Atorvastatin compounds, individual 2 . Displayed are the measured
concentrations (rhombs) with mean and standard deviation (n = 3) of Atorvastatin compounds in the culture medium (upper two rows) and
free Atorvastatin compounds inside primary hepatocytes (lower two rows) of individual 2, and corresponding simulation profiles (solid lines). First
and third row: AS (left), ASpOH (middle) and ASoOH (right). Second and fourth row: ASL (left), ASLpOH (middle) and ASLoOH (right).
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Discussion
The deterministic modeling of drug metabolism has a
major advantage compared to traditional pharmacoki-
netic models. The distinction between metabolism and
elimination inside the hepatocytes and the detailed
description of the biotransformation network structure
allows the observation of the reaction kinetics and the
transport mechanisms involved. Our modeling consid-
ered the major acid and lactone metabolites in the
extracellular and intracellular space as well as appropri-
ate reaction kinetics and transport steps. An experimen-
tal limitation in primary hepatocytes concerns the lower
limit of quantification of each metabolite. Therefore, a
relatively high initial concentration of AS of about 10
μM had to be chosen in order to permit measurement
of the described major metabolites. Interestingly, the
intracellular concentration of the parent drug AS was
higher than the extracellular concentration. This
indicates, that either the OATP mediated import does
rather follow an active uptake mechanism than the pro-
posed facilitated diffusion mechanism [58,59], or so far
unknown transporters may be involved in the transport
steps. By any means it justifies the chosen implementa-
tion of kinetics for the active mediated transport beside
the passive diffusion mechanism. In contrast to concen-
trations determined in plasma in clinical studies
[54,79,81], extracellular concentrations of the acidic
metabolites were much higher compared to the lactones.
A possible explanation of these discrepancies may be
that the in-vitro investigation on isolated primary
human hepatocytes was performed over rather short
time intervals (hours), whereas analyses in humans
usually cover longer periods (days). A second explana-
tion could be the relatively high initial concentration of
AS of about 10 μM used in this study, compared to
plasma concentrations observed to be lower than 200
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Figure 5 Measured concentrations and simulated fits of Atorvastatin compounds, individual 3 . Displayed are the measured
concentrations (rhombs) with mean and standard deviation (n = 3) of Atorvastatin compounds in the culture medium (upper two rows) and
free Atorvastatin compounds inside primary hepatocytes (lower two rows) of individual 3, and corresponding simulation profiles (solid lines and
dashed lines). First and third row: AS (left), ASpOH (middle) and ASoOH (right). Second and fourth row: ASL (left), ASLpOH (middle) and ASLoOH
(right). The dashed lines show the additional consideration of putative beta-oxidation of atorvastatin acids, AS, ASpOH and ASoOH, and of
adaptation of CYP3A4 and UGT1A3 protein concentrations in the model fit.
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(pmol ml-1). Furthermore, we found that the recovery of
metabolites decreases over the time. This confirms on
the one hand the contribution of unspecific binding to
macromolecules, most severely in the intracellular space,
as observed previously [35], but on the other hand
could also be contributed to a certain extent by the
unspecific binding to the collagen layer or the plates
[34], especially of highly lipophilic ASL and lactone
metabolites. However, due to the washing procedure
preliminary to the cell harvesting and disruption proce-
dure, this effect could not be observed in the chosen
experimental set-up.
The parameter identification was considered satisfac-
tory, as the simulation profiles fitted well to the corre-
sponding measured metabolite concentration data. But,
it was questionable if the optimized parameters could be
considered to be sensitive and identifiable. Therefore, a
local parameter sensitivity and identifiability analysis
based on the Fisher-Information-Matrix was performed.
The results showed that the full model of AS metabo-
lism is not identifiable. Consequently a model reduction
procedure was set-up and could be applied successfully,
indicating that the parameter identification difficulties
are caused by non-identifiable transporter steps, dis-
played by low parameter sensitivities and high parameter
errors and correlations, which were then reduced in the
model. However, this outcome does not necessarily
mean that the non-identifiable transport steps are not
present or not used in human hepatocytes, but rather
implies, that they cannot be distinguished from the
remaining transport steps in the model verification.
Thus, the remaining transport steps in the model cap-
ture the probable superimposed contribution of several
transport mechanisms in-vivo.
Unfortunately, the local identifiability of the final
model version reveals some uncertainties caused by
remaining high correlations present in the transport
steps, as well as in the intracellular reaction network.
An additional problem attributed to the modeling and
parameter optimization is related to the fact that several
parameters have lumped characteristics, because they
are used for more than one compound, like the fraction
Table 5 Parameter Variability in the simultaneous model
verification on individual atorvastatin metabolism data.
Parameter Individual
1
Individual
2
Individual
3
Units
rmax,3A4,
ASpOH
1108 660 606 pmol·min-1·ml-1
rmax,3A4,
ASoOH
3345 1991 1830 pmol·min-1·ml-1
rmax,3A4,
ASLpOH
1228 731 672 pmol·min-1·ml-1
rmax,3A4,
ASLoOH
2756 1640 1508 pmol·min-1·ml-1
rmax,1A3,AS 957 281 120 pmol·min
-1·ml-1
PON,ASL 308 99.2 0.00 10
-3 min-1
PON,ASLOH 280 545 82.9 10
-3 min-1
ex,AS 2.17 0.16 0.17 μL·min
-1
ex,ASL 21.8 2.48 10.5 μL·min
-1
ex,ASpOH, 0.80 1.25 0.52 μL·min
-1
ex,ASoOH 1.60 3.62 0.91 μL·min
-1
ex,ASLpOH 1.13 1.01 0.59 μL·min
-1
ex,ASLoOH 2.67 86.3 0.77 μL·min
-1
im.AS 20.3 4.42 3.45 μL·min
-1
im.ASL 275 25.8 82.7 μL·min
-1
im,ASpOH 3.96 2.01 2.53 μL·min
-1
im,ASoOH 0.39 0.22 0.00 μL·min
-1
ex,ASLpOH 33.7 7.24 8.59 μL·min
-1
im,ASLoOH 26.1 530 2.43 μL·min
-1
kB-Ox,AS 15.0 10
-3 min-1
kB-Ox,ASOH 0.00 10
-3 min-1
Parameters are listed for the individuals 1, 2 and 3 with nominal values from
optimization in the corresponding units shown.
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Figure 6 Individual variability of CYP3A4 and UGT1A3 protein
concentration level. Displayed is the distribution of CYP3A4 (top)
and UGT1A3 (bottom) protein concentration data of individual
human liver microsomes (n = 150). Protein concentrations are
normalized to minimal value, respectively.
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unbound factor, which is set to be the same for all
acidic or lactone AS compounds, respectively. A possible
solution would be to set individual parameters for each
compound. However, then the parameter identifiability
difficulties would be even more severe. This is due to
the fact, that the experimental observation on primary
human hepatocytes is constrained strongly on several
limitations. For example, the range of initial concentra-
tions is strongly limited to the quantification of metabo-
lites of interest. Further, the number of data points is
strongly limited to the available cell number of primary
hepatocytes, isolated from surgery removal. Finally, also
the individual character of human cells due to individual
genetic and medical background precludes an exact
reproduction of experiments and the reproducibility of
experimental results. The remaining parameter uncer-
tainty seems to be crucial for the prediction of the
population probability on the first sight. Actually, this is
not the case. Since the parameter errors and the correla-
tions indicate which parameter changes in what extent
do not influence the computed time courses, the varia-
bility in the respective parameter error range would not
influence the probability distributions. In general, the
question if parameter errors and insensitivities are suffi-
ciently small can only be answered when knowing the
requirements of the pharmacological application as
drug, which was not given in this study.
The simultaneous model verification based on primary
human hepatocytes from different individuals illustrates
the individual character of drug metabolism in the liver.
Further, it indicates the inter-individual variability of rate
parameters not only of the phase I and II enzymes, but
also of the transport enzymes. In case of patients with
type 2 diabetes, AS metabolism is probably influenced
strongly by beta-oxidation and further so far unknown
effects. Therefore, the individual model verification might
also be used to reveal undesired pharmacokinetic effects.
However, this analysis tool should be checked carefully
on other drug systems in the future, too.
The individual nature of the AS metabolism was investi-
gated in this study in the domain of inter-individual varia-
bility of CYP3A4 and UGT1A3 protein expression levels
in human hepatocytes, by performing dynamic analysis on
the verified model, individualized by implementation of a
comprehensive set of protein data from a liver bank. The
results show, that the inter-individual variability strongly
affects the biotransformation behavior and therefore
reveals the individual character of AS metabolism.
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Figure 7 Distributions from dynamic analysis of the Inter-
individual variability in Atorvastatin metabolism. Distributions
(bars) of AUC (top), cmax (middle) and of t(cmax) (bottom), and fitted
probability density functions of simulated profiles of AS (solid lines)
and of the sum of AS, ASpOH and ASoOH (dashed lines),
respectively. Distributions are predicted by the dynamic simulation
of Atorvastatin metabolism, implementing individual CYP3A4 and
UGT1A3 protein concentration data (Figure 6).
Table 6 Probability density functions fitted to inter-
individual variability distributions
Probability density
function
Mean s.d. rel. s.d.
[%]
AUC [pmol ml-1*min]
AS Log-logistic 75051 92038 123
AS+ASpOH+ASoOH Log-logistic 203617 35775 18
cmax [pmol ml
-1]
AS Log-logistic 201 64 32
AS+ASpOH+ASoOH Log-logistic 366 10 3
t(cmax) [min]
AS Log-logistic 48 18 39
AS+ASpOH+ASoOH Log-logistic 100 12 12
Probability density functions fitted to distributions of AUC, cmax and t(cmax)
(depicted in Figure 7), generated in dynamic simulations considering inter-
individual variability of CYP3A4 and UGT1A3 protein concentration data
(Figure 6). Distributions of AUC, cmax and t(cmax) were fitted best with Log-
logistic function. Displayed are the mean, the standard deviation (s.d.), and
the relative standard deviation (rel. s.d.) of the fitted function, respectively.
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Consequently, this individuality in the pharmacokinetics of
AS also points out the individual character of pharmaco-
dynamics at the drug target, namely the HMGCoA-reduc-
tase in human hepatocytes.
However, this subject-variability can also be expected
to be present in the transport protein expression, as
previously shown for OATP-C [82]. Therefore, this
variability should be taken into account in the future by
implementing corresponding population expression data
in the dynamic analysis. Another source of variation
is the well-known polymorphism in CYP- and UGT-
enzymes and likely transport proteins, which very prob-
ably causes inter-individual variations of the catalytic
activity and the substrate affinity KM. Thus, further
efforts should also consider this individual difference,
leading to the improvement of the model prediction.
To resolve the contributing transport mechanisms in
more detail, additional information should be imple-
mented from transport investigations on recombinant
systems, as described previously [72,83], which enable
the differentiated identification of both basolateral and
apical transporters of AS and the corresponding trans-
port kinetics. Further, also the estimation of unspecific
drug protein binding could be improved in the future by
using radiolabeled compounds in the experiments and
modeling approaches as described previously [60,69].
Conclusions
We believe that the results of our simulations provide
strong arguments for rigorous dynamic modeling of drug
biotransformation at the cellular level embedded in a sys-
tems biology approach. By resolving the detailed metabolic
network structure with metabolites and catalyzing
enzymes, we investigated the dynamic variation of atorvas-
tatin metabolism affected by the inter-individual variability
of expression levels of phase I and phase II enzymes.
In contrast to experimental investigations on recombi-
nant systems or tissue fractions of hepatocytes, like
microsomes, the investigation on primary human hepa-
tocytes enabled the holistic and most realistic in-vitro
observation of drug biotransformation, because it is pos-
sible to observe the coupled contribution of metabolism
and transport to the entire processes. De novo of this
study, we identified intracellular concentration profiles
of atorvastatin metabolites in primary human hepato-
cytes in a time-series approach.
Such an approach is essential for integration of
further-reaching issues, such as drug-drug interactions,
impact of regulation networks linked to nuclear recep-
tors and particularly to quantitatively account for sub-
ject-variability. The integration of this variability caused
by genetic or environmental variations is crucial for pre-
dictive pharmacokinetic modeling.
Such a rigorous modeling approach critically depends
upon a tight link between experimental observations
and model design, simulation and verification. While the
results are promising, some limitations in the parameter
identification were still encountered. In the long term,
these open problems can only be solved by stronger
links to other research areas, such as pharmacogenetics,
characterization of transporters, etc. On the whole, our
contention is that the problem of parameter identifiabil-
ity is an indispensable ingredient of model verification.
Systematic investigations - if possible linked to optimal
experimental design - can greatly strengthen the cred-
ibility of the models.
However, we present a model that goes much further.
The domain of application does not remain the system
behavior for which it has been elaborated. The model
provides the possibility to link further modules such as
gene regulation, drug target metabolism and present the
important links to be implemented into the PBPK envir-
onment. Finally, the model structure used in this study
should be considered as a module to be integrated into
the framework of multi-scale whole body modeling and
simulations necessary to tackle the drug disposition in
patient populations.
Additional material
Additional file 1: Derivation of atorvastatin kinetics at CYP3A4. This
file contains the derivation of the atorvastatin kinetics at CYP3A4, which
describes the competition of alternative substrate degradation to
alternative products (supplemented as .pdf-file).
Additional file 2: Derivation of kinetics of unspecific binding to
macromolecules. This file contains the derivation of kinetics of the
unspecific binding of atorvastatin metabolites to macromolecules, for
example proteins (supplemented as .pdf-file).
Additional file 3: Atorvastatin metabolite concentrations from the
time-series experiment on primary human hepatocytes of
individual 1. Extracellular concentrations (upper part) and intracellular
concentrations (lower part) of atorvastatin acid and lactone (AS and ASL)
and corresponding para- and ortho-hydroxy-metabolites (acids: ASpOH
and ASoOH; lactones: ASLpOH and ASLoOH) at the defined time-points
with mean and standard deviation (n = 3) from triplicate measurements
per LC-MS/MS (n.d.: not determinable; n.o.: not observed). The recovery is
calculated from material balance equations and is defined as the sum of
intracellular and extracellular metabolite amounts at the respective time-
point divided by initial AS amount (supplemented as .pdf-file).
Additional file 4: Analysis of parameter sensitivity and following
model reduction procedure. This file contains the analysis of parameter
sensitivity and the exemplary model reduction procedure, which is
necessary for achieving a high quality predictive model of atorvastatin
metabolism (supplemented as .pdf-file).
Additional file 5: Atorvastatin metabolite concentrations from the
time-series experiment on primary human hepatocytes of
individual 2. Extracellular concentrations (upper part) and intracellular
concentrations (lower part) of atorvastatin acid and lactone (AS and ASL)
and corresponding para- and ortho-hydroxy-metabolites (acids: ASpOH
and ASoOH; lactones: ASLpOH and ASLoOH) at the defined time-points
with mean and standard deviation (n = 3) from triplicate measurements
per LC-MS/MS (n.d.: not determinable) (supplemented as .pdf-file).
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Additional file 6: Atorvastatin metabolite concentrations from the
time-series experiment on primary human hepatocytes of
individual 3. Extracellular concentrations (upper part) and intracellular
concentrations (lower part) of atorvastatin acid and lactone (AS and ASL)
and corresponding para- and ortho-hydroxy-metabolites (acids: ASpOH
and ASoOH; lactones: ASLpOH and ASLoOH) at the defined time-points
with mean and standard deviation (n = 3) from triplicate measurements
per LC-MS/MS (n.d.: not determinable) (supplemented as .pdf-file).
Additional file 7: Model of atorvastatin metabolism in primary
human hepatocytes of individual 1. The sbml-file contains the model
of Atorvastatin metabolism in human hepatocytes with the model
parameters identified on primary human hepatocytes of individual 1
(supplemented as .xml-file).
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AS: atorvastatin acid; ASL: atorvastatin lactone; ASOH: hydroxy-atorvastatin
acids (para- and ortho-); ASpOH: para-hydroxy-atorvastatin acid; ASoOH:
ortho-hydroxy-atorvastatin acid; ASLOH: hydroxy-atorvastatin lactones (para-
and ortho-); ASLpOH: para-hydroxy-atorvastatin lactone; ASLoOH: ortho-
hydroxy-atorvastatin lactone; B-OX: beta-oxidation of atorvastatin acids; c:
index: intracellular (cytosol); calc: index: calculated; CR: index: chemical
reaction of hydrolysis of lactones; CYP: cytochrome P450 monooxygenase;
Den: Denominator; e: index: enzyme; eq: Index: equilibrium; ex: index: export;
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